1. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
- Author
-
David Majewski, Delia J. Nelson, Anna K. Nowak, Simon A. Fox, and Connie Jackaman
- Subjects
Cytotoxicity, Immunologic ,Mesothelioma ,Cancer Research ,Subdominant ,Ovalbumin ,Immunology ,Antineoplastic Agents ,chemical and pharmacologic phenomena ,CD8-Positive T-Lymphocytes ,Biology ,Transfection ,Deoxycytidine ,Epitope ,Epitopes ,Interferon-gamma ,Mice ,Immune system ,Antigen ,Antigens, Neoplasm ,Cell Line, Tumor ,MHC class I ,Animals ,Immunology and Allergy ,Cytotoxic T cell ,Antigen Presentation ,Histocompatibility Antigens Class I ,Gemcitabine ,Tumor antigen ,Mice, Inbred C57BL ,CTL ,Oncology ,biology.protein ,Interleukin-2 ,Female ,Cisplatin ,T-Lymphocytes, Cytotoxic - Abstract
Cytotoxic chemotherapies may expose the immune system to high levels of tumor antigens and expand the CD8(+) T-cell response to include weak or subdominant antigens. Here, we evaluated the in vivo CTL response to tumor antigens using a murine mesothelioma tumor cell line transfected with a neotumor antigen, ovalbumin, that contains a known hierarchy of epitopes for MHC class I molecules. We show that as tumors progress, effector CTLs are generated in vivo that focus on the dominant epitope SIINFEKL, although a weak response was seen to one (KVVRFDKL) subdominant epitope. These CTLs did not prevent tumor growth. Cisplatin treatment slowed tumor growth, slightly improved in vivo SIINFEKL presentation to T cells and reduced SIINFEKL-CTL activity. However, the CTL response to KVVRFDKL was amplified, and a response to another subdominant epitope, NAIVFKGL, was revealed. Similarly, gemcitabine cured most mice, slightly enhanced SIINFEKL presentation, reduced SIINFEKL-CTL activity yet drove a significant CTL response to NAIVFKGL, but not KVVRFDKL. These NAIVFKGL-specific CTLs secreted IFNγ and proliferated in response to in vitro NAIVFKGL stimulation. IL-2 treatment during chemotherapy refocused the response to SIINFEKL and simultaneously degraded the cisplatin-driven subdominant CTL response. These data show that chemotherapy reveals weaker tumor antigens to the immune system, a response that could be rationally targeted. Furthermore, while integrating IL-2 into the chemotherapy regimen interfered with the hierarchy of the response, IL-2 or other strategies that support CTL activity could be considered upon completion of chemotherapy.
- Published
- 2012
- Full Text
- View/download PDF